Elanco Animal Health (ELAN) to Release Quarterly Earnings on Wednesday

Key Points

• Elanco will report Q1 2026 results before the market opens on May 6, 2026 at 8:00 AM ET; analysts expect $0.35 EPS and $1.279 billion in revenue, and the company guided Q1 EPS to 0.330–0.36 and FY 2026 EPS to 1.000–1.060.
• In its most recent quarter (reported Feb. 24) Elanco beat estimates with $0.13 EPS (vs. $0.11 consensus) and $1.14 billion in revenue (up 12.2% YoY), but the company still showed a negative net margin of -4.92%.
• Analysts are broadly positive (consensus rating: Moderate Buy) with a $27.90 average price target after several upgrades, while the stock trades around $22.20 with a 52-week range of $9.32–$27.72 and a market cap of $11.04 billion.

Elanco Animal Health (NYSE:ELAN - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $1.2792 billion for the quarter. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm's revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 earnings per share. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $22.20 on Wednesday. The stock's fifty day moving average is $23.98 and its two-hundred day moving average is $23.25. The firm has a market capitalization of $11.04 billion, a P/E ratio of -46.24, a price-to-earnings-growth ratio of 2.82 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. Elanco Animal Health has a fifty-two week low of $9.32 and a fifty-two week high of $27.72.

Analyst Ratings Changes

A number of equities analysts have weighed in on ELAN shares. Morgan Stanley boosted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 25th. KeyCorp boosted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Thursday, February 19th. Leerink Partners boosted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. Finally, UBS Group reissued a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $27.90.

Hedge Funds Weigh In On Elanco Animal Health

Several large investors have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its holdings in shares of Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company's stock worth $160,000 after acquiring an additional 392 shares during the last quarter. Lazard Asset Management LLC raised its holdings in shares of Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company's stock valued at $1,631,000 after buying an additional 425 shares during the period. Meeder Advisory Services Inc. raised its holdings in shares of Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company's stock valued at $254,000 after buying an additional 510 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after buying an additional 627 shares during the period. Finally, Arkadios Wealth Advisors raised its holdings in shares of Elanco Animal Health by 1.2% in the 4th quarter. Arkadios Wealth Advisors now owns 52,868 shares of the company's stock valued at $1,196,000 after buying an additional 652 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.